9.99
price up icon1.73%   0.17
after-market After Hours: 9.82 -0.17 -1.70%
loading
Dbv Technologies Adr stock is traded at $9.99, with a volume of 21,124. It is up +1.73% in the last 24 hours and down -1.72% over the past month. DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
See More
Previous Close:
$9.82
Open:
$10.02
24h Volume:
21,124
Relative Volume:
0.47
Market Cap:
$273.62M
Revenue:
-
Net Income/Loss:
$-102.09M
P/E Ratio:
-9.5143
EPS:
-1.05
Net Cash Flow:
$-108.72M
1W Performance:
+1.73%
1M Performance:
-1.72%
6M Performance:
+127.30%
1Y Performance:
+111.43%
1-Day Range:
Value
$9.72
$10.16
1-Week Range:
Value
$9.328
$10.16
52-Week Range:
Value
$2.2045
$12.78

Dbv Technologies Adr Stock (DBVT) Company Profile

Name
Name
Dbv Technologies Adr
Name
Phone
33(0)155427878
Name
Address
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Name
Employee
109
Name
Next Earnings Date
2024-07-29
Name
Latest SEC Filings
Name
DBVT's Discussions on Twitter

Compare DBVT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
DBVT
Dbv Technologies Adr
9.99 268.69M 0 -102.09M -108.72M -1.05
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
392.79 100.07B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
580.41 59.99B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
448.91 58.03B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
653.83 39.93B 3.06B 1.28B -614.78M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
321.36 36.82B 3.81B -644.79M -669.77M -6.24

Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades

Date Action Analyst Rating Change
May-29-25 Resumed Goldman Sell
Jan-04-23 Upgrade Societe Generale Hold → Buy
Dec-16-22 Downgrade Goldman Neutral → Sell
May-10-22 Downgrade Goldman Buy → Neutral
Sep-14-21 Upgrade Societe Generale Hold → Buy
Jan-22-21 Downgrade Societe Generale Hold → Sell
Nov-02-20 Upgrade Societe Generale Sell → Hold
Aug-06-20 Downgrade Societe Generale Buy → Sell
Aug-05-20 Reiterated H.C. Wainwright Buy
Mar-17-20 Downgrade Stifel Buy → Hold
Jan-09-20 Upgrade Stifel Hold → Buy
Dec-16-19 Initiated Citigroup Buy
Sep-05-19 Resumed Morgan Stanley Equal-Weight
Jun-17-19 Initiated Goldman Buy
Dec-20-18 Downgrade Barclays Overweight → Equal Weight
Dec-20-18 Downgrade BofA/Merrill Buy → Underperform
Dec-20-18 Downgrade Jefferies Buy → Hold
Dec-20-18 Downgrade Stifel Buy → Hold
Oct-31-17 Upgrade Societe Generale Sell → Hold
Oct-24-17 Downgrade Societe Generale Buy → Sell
Oct-23-17 Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-23-17 Initiated Deutsche Bank Buy
Mar-16-17 Upgrade Societe Generale Hold → Buy
Sep-26-16 Initiated JMP Securities Mkt Outperform
Dec-03-15 Initiated Barclays Overweight
Oct-23-15 Initiated BofA/Merrill Buy
View All

Dbv Technologies Adr Stock (DBVT) Latest News

pulisher
Aug 15, 2025

European Biopharma ADRs: A Strategic Play in a Volatile Market - AInvest

Aug 15, 2025
pulisher
Aug 09, 2025

European ADRs Edge Higher While Sector Winners And Losers Diverge - Finimize

Aug 09, 2025
pulisher
Aug 06, 2025

Does DBV Technologies S.A. Depositary Receipt fit your quant trading modelAlpha Generation Strategy with Low Volatility - Newser

Aug 06, 2025
pulisher
Aug 02, 2025

HC Wainwright Lowers Earnings Estimates for DBV Technologies - Defense World

Aug 02, 2025
pulisher
Aug 01, 2025

DBV Technologies Maintains Buy Rating with €6.00 Target from Kepler Capital's Justine Telliez - AInvest

Aug 01, 2025
pulisher
Jul 29, 2025

DBV Technologies Announces Filing of 2025 Half-Year Report - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report - GlobeNewswire

Jul 29, 2025
pulisher
Jul 29, 2025

DBV Technologies S.A. - Via Ritzau

Jul 29, 2025
pulisher
Jul 29, 2025

DBV Technologies Releases Latest Financial Report: Food Allergy Treatment Progress Updates Inside - Stock Titan

Jul 29, 2025
pulisher
Jul 29, 2025

DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results - GlobeNewswire

Jul 29, 2025
pulisher
Jul 28, 2025

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - The Manila Times

Jul 28, 2025
pulisher
Jul 28, 2025

DBV Technologies Liquidity Contract Update: Over €3M in Trading Volume Reveals Market Activity - Stock Titan

Jul 28, 2025
pulisher
Jul 27, 2025

DBV Technologies (DBVT) Projected to Post Quarterly Earnings on Tuesday - Defense World

Jul 27, 2025
pulisher
Jul 25, 2025

DBV Technologies S.A. (NASDAQ:DBVT) Receives $14.75 Average PT from Analysts - Defense World

Jul 25, 2025
pulisher
Jul 24, 2025

European ADRs Inch Higher As Drugmakers Shine - Finimize

Jul 24, 2025
pulisher
Jul 22, 2025

DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

DBV Technologies Taps Healthcare Veteran as CHRO to Drive Commercial Evolution - Stock Titan

Jul 22, 2025
pulisher
Jul 20, 2025

What analysts say about DBV Technologies S.A. Depositary Receipt stockHigh-impact stock picks - Autocar Professional

Jul 20, 2025
pulisher
Jul 14, 2025

European Stocks In The US Finish With A Modest Rebound - Finimize

Jul 14, 2025
pulisher
Jul 13, 2025

Analysts Are Bullish on Top Healthcare Stocks: Neurogene (NGNE), Cogent Biosciences (COGT) - The Globe and Mail

Jul 13, 2025
pulisher
Jul 10, 2025

European ADRs Climb As Verona Pharma Leads Gains - Finimize

Jul 10, 2025
pulisher
Jul 09, 2025

European ADRs Climb As Sequans Leads The Charge - Finimize

Jul 09, 2025
pulisher
Jul 07, 2025

DBV Technologies’ SWOT analysis: peanut allergy patch stock poised for growth - Investing.com India

Jul 07, 2025
pulisher
Jul 05, 2025

DBV Technologies (NASDAQ:DBVT) Upgraded to Hold at Wall Street Zen - Defense World

Jul 05, 2025
pulisher
Jul 01, 2025

European Stocks Climb As ADRs Post Gains - Finimize

Jul 01, 2025
pulisher
Jul 01, 2025

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Jul 01, 2025
pulisher
Jun 30, 2025

European ADRs: Navigating Sectoral Divergence in a Volatile Market - AInvest

Jun 30, 2025
pulisher
Jun 28, 2025

Lifesci Capital Upgrades DBV Technologies (NASDAQ:DBVT) to Strong-Buy - Defense World

Jun 28, 2025
pulisher
Jun 27, 2025

European Biopharma Leads Gains In ADR Market Surge - Finimize

Jun 27, 2025
pulisher
Jun 27, 2025

European Biotech ADRs Lead the Charge: A Sector on the Verge of Breakthrough Growth - AInvest

Jun 27, 2025
pulisher
Jun 26, 2025

European ADRs Dip As Biotech Stocks Show Mixed Results - Finimize

Jun 26, 2025
pulisher
Jun 26, 2025

DBV Technologies stock holds steady as JMP reiterates $21 price target - Investing.com

Jun 26, 2025
pulisher
Jun 25, 2025

Breakthrough Peanut Allergy Treatment Enters Critical Phase 3 Trial for Toddlers as Young as 12 Months - Stock Titan

Jun 25, 2025
pulisher
Jun 21, 2025

European ADRs Dip As Evaxion And Grifols Climb - Finimize

Jun 21, 2025
pulisher
Jun 18, 2025

European ADRs Dip While Biotech And Energy See Gains - Finimize

Jun 18, 2025
pulisher
Jun 16, 2025

European Stocks Shine As ADRs Climb Higher - Finimize

Jun 16, 2025
pulisher
Jun 14, 2025

DBV Technologies (NASDAQ:DBVT) Stock Price Crosses Above 50 Day Moving Average – Here’s Why - Defense World

Jun 14, 2025
pulisher
Jun 12, 2025

DBV Technologies to Participate in Upcoming EAACI Congress 2025 - The Manila Times

Jun 12, 2025

Dbv Technologies Adr Stock (DBVT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$36.35
price down icon 0.41%
$86.92
price up icon 0.88%
$26.69
price up icon 0.91%
$127.80
price up icon 0.04%
$113.52
price up icon 0.73%
biotechnology ONC
$321.36
price up icon 3.77%
Cap:     |  Volume (24h):